BofA lowered the firm’s price target on Apellis (APLS) to $41 from $44 and keeps a Buy rating on the shares. The firm updated models in ...

In this article, we are going to take a look at where Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) stands against other most oversold healthcare stocks to buy now. Healthcare costs and spending ...

Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Apellis Pharmaceuticals (APLS – Research Report) today and set a ...

After several weeks and thousands of votes, TV drug ads from Apellis Pharmaceuticals and AstraZeneca found themselves in the final round of the annual #FierceMadness bracket competition. | After ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Apellis Pharmaceuticals, Inc.’s APLS share price has dipped by 11.32%, which has investors questioning if this is right time to buy.

Apellis Pharmaceuticals has announced US FDA acceptance of the supplemental new drug application (sNDA) and the granting of priority review status to Empaveli (pegcetacoplan) to treat the rare and ...

In this article, we are going to look at where Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) stands against other biotech stocks. The biotechnology sector is gaining new momentum with better market ...

In trading on Monday, shares of Apellis Pharmaceuticals Inc (Symbol: APLS) entered into oversold territory, hitting an RSI reading of 26.7, after changing hands as low as $21.89 per share.

1 Day APLS -4.22% DJIA -0.60% S&P Mid Cap 400 -0.18% Health Care/Life Sciences 0.16% The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent ...

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the Phase 2 MERIDIAN study investigating systemic pegcetacoplan ...